Abstract:e13574 Background: Emerging evidence has proven that tertiary lymphoid structures (TLSs) are predictive biomarkers of favorable clinical outcomes in melanoma, whereas the exact role of TLS-related genes remained unclear. In the present study, we aimed to establish a novel risk-scoring model based on TLS-related genes to predict the prognosis and immunotherapeutic efficacy in cutaneous melanoma. Methods: Patients in the TCGA-SKCM cohort (n = 468) were clustered into two subtypes based on the prognosis-related genes associated with TLSs though consensus clustering analysis, and differentially expressed genes were screened between two clusters. By univariate and the least absolute shrinkage and selection operator (LASSO) Cox regression analysis, a 13-gene signature was selected to construct a prognostic risk-scoring model. The median risk score served as the unified cutoff to divide patients into high- and low-risk groups. GSE65904 (n = 220) and GSE544467 (n = 79) cohorts were used for external validation. Univariate and multivariate cox analysis were used to select significant variables for construction of nomogram. The nomogram model was evaluated by concordance index, time-dependent receiver operating characteristics (ROC) curve, calibration curve and decision curve analysis (DCA). GSEA, CIBERSORT, Tumor Immune Dysfunction and Exclusion (TIDE) and Immunophenoscore (IPS) were utilized to explore the potential mechanism of immune-related process and immunotherapy. Results: Thirteen signature genes (CCL8, DLX3, CNTFR, CNFN, BCAN, CD33, HAPLN3, ABCB1, CLIC2, GCNT1, FGF1, A2ML1, GBP2) were developed to construct a risk-scoring model. Melanoma patients could be grouped into high- and low-risk groups, and low-risk patients showed better survival than high-risk patients. Area under the curve values of 1, 3, and 5 years were 0.76, 0.72, and 0.73 in the training set, respectively, indicating a good predictive efficacy. In addition, based on independent prognostic factors including risk score, age, stage, T and N Staging after univariate and multivariate Cox regression analyses, a nomogram was constructed to better estimate individual survival. For the prediction of 1, 3, and 5-year overall survival probability according to the nomogram, the area under the receiver operating characteristic curve was 0.81, 0.80 and 0.76, respectively. Furthermore, we explored the correlation of the prognostic risk-scoring model with tumor microenvironment (TME) and immunotherapeutic efficacy. Patients in the low risk group featured immunoactive TME, higher IPS scores and lower TIDE scores, and was regarded as the potential beneficiaries of immunotherapy. Conclusions: The 13-gene risk score proposed in the research may provide new insights into the individualized evaluation of cutaneous melanoma prognosis and Immunotherapeutic Efficacy

Clinical Significance and Immune Landscape of KIR2DL4 and the Senescence‐based Signature in Cutaneous Melanoma

Senescence-Related lncRNA Signature Predicts Prognosis, Response to Immunotherapy and Chemotherapy in Skin Cutaneous Melanoma

Development and validation of Cellular Senescence-Related Gene Signature for predicting the survival and immunotherapeutic responses in Skin Cutaneous Melanoma

Prognostic model for clear-cell renal cell carcinoma based on natural killer cell-related genes.

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 Protein Expression in Non-Small Cell Lung Cancer

A Combined Aging and Immune Prognostic Signature Predict Prognosis and Responsiveness to Immunotherapy in Melanoma

Construction and Identification of an NLR-Associated Prognostic Signature Revealing the Heterogeneous Immune Response in Skin Cutaneous Melanoma

Prediction of Clinical Prognosis in Cutaneous Melanoma Using an Immune-Related Gene Pair Signature

Identification of the ageing-related prognostic gene signature, and the associated regulation axis in skin cutaneous melanoma

A novel risk-scoring model developed based on tertiary lymphoid structure related genes predict the prognosis and immunotherapeutic efficacy in cutaneous melanoma.

Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis

Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma

Characterization of Aging-Related Genes to Predict Prognosis and Evaluate the Tumor Immune Microenvironment in Malignant Melanoma

Impact of senescence cell signature in patients with non-small cell carcinoma and melanoma receiving PD-L1/PD-1 inhibitors

Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.

Predicting the clinical outcome of melanoma using an immune-related gene pairs signature

Identification of anoikis-related subtypes and development of risk stratification system in skin cutaneous melanoma

Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma

Leveraging a Cuproptosis-Based Signature to Predict the Prognosis and Drug Sensitivity of Cutaneous Melanoma

Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma

A novel risk model based on anoikis: Predicting prognosis and immune infiltration in cutaneous melanoma